UNSPSC 51183204: Tolrestat

This classification denotes an aldose reductase inhibitor with the molecular formula C16H14F3NO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 0T93LG5NMK, chemically known as glycine, n-((6-methoxy-5-(trifluoromethyl)-1-naphthalenyl)thioxomethyl)-n-methyl- but more generally known as tolrestat, which bears US NIH Compound Identifier 53359. European Medicines Agency schedules Tolrestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11179MIG.

UNSPSC 51183204 Tolrestat is a Commodity code identifying a specific pharmaceutical active ingredient used in state and local procurement for diabetes management and related endocrine therapies. Tolrestat is an aldose reductase inhibitor historically developed to treat diabetic complications, though its clinical use and availability have been limited in recent years. State and local health agencies, correctional facilities, hospital systems, and public health departments source this medication when required for eligible patient populations under formulary guidelines or therapeutic protocols. Procurement under this code typically flows through established pharmaceutical supply contracts, group purchasing organizations, or state Medicaid programs that manage bulk purchasing and distribution to public facilities.

The source provided does not include a recent-opportunities block with specific solicitations, issuing bodies, or response dates for UNSPSC 51183204. No recent state and local RFP, RFQ, IFB, or ITB activity is documented for this commodity code, and geographic distribution cannot be characterized. The absence of recent procurement records suggests either minimal current demand for tolrestat within state and local government purchasing, limited availability through standard pharmaceutical supply channels, or routing of procurement through existing master-service agreements rather than discrete bid notices. Firms pursuing this code should verify current formulary inclusion and clinical adoption rates within target state Medicaid programs and public health systems before building business development strategy around tolrestat sourcing.